Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listDISOPYRAMIDE

DISOPYRAMIDE

Synonym(s):α-Diisopropylaminoethyl-α-phenylpyridine-2-acetamide

  • CAS NO.:3737-09-5
  • Empirical Formula: C21H29N3O
  • Molecular Weight: 339.48
  • MDL number: MFCD00057366
  • EINECS: 223-110-2
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
DISOPYRAMIDE Structural

What is DISOPYRAMIDE?

Absorption

Nearly complete

Toxicity

LD50=580 mg/kg in rats

Description

Structurally, disopyramide does not belong to any of the known classes of antiarrhythmics; however, being a drug of the class IA sodium channel blockers, it exhibits membranestabilizing action and increases the effective refractory period and duration of an action potential in the atrium and ventricles. It causes a decrease in contractability and excitability of the myocardium, slowing of conductivity, and suppression of sinoatride automatism.

Chemical properties

Crystalline Solid

Originator

Rythmodan,Cassenne,France,1969

The Uses of DISOPYRAMIDE

Disopyramide is used for preventing and restoring atrial and ventricular extrasystole and tachycardia in order to prevent atrial flutter and arrhythmia.

The Uses of DISOPYRAMIDE

Antiarrhythmic (class IA). Sodium channel blocker

The Uses of DISOPYRAMIDE

Antiarrhythmic;Na+ channel blocker

Indications

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.

Background

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

What are the applications of Application

Disopyramide is an antiarrhythmic (class IA) and a sodium channel blocker

Definition

ChEBI: A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.

Manufacturing Process

To a solution of 35.3 parts of phenylacetonitrile and 47.6 parts of 2- bromopyridine in 175 parts of dry toluene is added 53.4 parts of sodamide slowly with stirring over a period of 45 minutes. The resultant mixture is stirred at 100°C for 2 hours before it is cooled and the excess sodamide is decomposed by the addition of water. The toluene layer is separated and washed with water to remove excess alkali. The toluene solution is extracted with 6 N hydrochloric acid and the acid extract is made alkaline and then extracted with toluene. The toluene solution is dried over sodium sulfate and the solvent is evaporated. Recrystallization of the residue from alcohol-hexane gives α-phenyl-2-pyridineacetonitrile melting at about 87-88°C.
To a solution of 41 parts of α-phenyl-2-pyridineacetonitrile in 350 parts of dry toluene is added 9.2 parts of sodamide and the mixture is stirred and heated at 90°C for 30 minutes. Heating is stopped and a solution of 38.5 parts of 2- diisopropylaminoethyl chloride in 110 parts of dry toluene is added slowly over a period of 30 minutes. The mixture is stirred and refluxed for 6 hours before it is cooled and decomposed by the addition of water. The toluene layer is separated and washed with water and extracted with 6 N hydrochloric acid. The acid extract is made alkaline and extracted with toluene. The toluene solution is washed with water and dried and the solvent is evaporated. Distillation of the residue gives 4-diisopropylamino-2-phenyl-2-(2-pyridyl)- butyronitrile boiling at about 145°-160°C at 0.3 mm pressure.
A solution of 27.2 parts of 4-diisopropylamino-2-phenyl-2-(2- pyridyl)butyronitrile in 200 parts of concentrated sulfuric acid is heated on a steam bath for 4 hours and then poured onto ice. The resultant mixture is alkalized with 10 N sodium hydroxide, and the pH is adjusted to 6 by the addition of acetic acid. The solution is washed once with benzene before it is alkalized again with 10 N sodium hydroxide solution. The resultant mixture is extracted with benzene, and the solvent is evaporated from the benzene extract. The resultant residue is dissolved in ethanol and the alcohol solution is treated with charcoal and filtered. Evaporation of the solvent leaves a residue which is recrystallized from hexane to give 4-diisopropylamino-2- phenyl-2-(2-pyridyl)butyramide melting at about 94.5-95°C. It may be converted to the phosphate with phosphoric acid.

brand name

Norpace (Searle).

Therapeutic Function

Antiarrhythmic

Mechanism of action

Disopyramide has a pharmacological profile similar to that of quinidine and procainamide . Clinically, it is active against most forms of arrhythmias (supraventricular and ventricular).

Pharmacokinetics

Disopyramide is an anti-arrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. At therapeutic plasma levels, disopyramide shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.

Pharmacokinetics

Disopyramide phosphate is used orally for the treatment of certain ventricular and atrial arrhythmias. Despite its structural dissimilarity to procainamide, its cardiac effects are very similar. Disopyramide is rapidly and completely absorbed from the gastrointestinal tract. Peak plasma level is usually reached within 1 to 3 hours, and a plasma half-life of 5 to 7 hours is common. Approximately half of an oral dose is excreted unchanged in the urine. The remaining drug undergoes hepatic metabolism, principally to the corresponding N-dealkylated form. This metabolite retains approximately half the antiarrhythmic activity of disopyramide and also is subject to renal excretion.

Clinical Use

Disopyramide (Norpace) can suppress atrial and ventricular arrhythmias and is longer acting than other drugs in its class.
The indications for use of disopyramide are similar to those for quinidine, except that it is not approved for use in the prophylaxis of atrial flutter or atrial fibrillation after DC conversion.The indications are as follows: unifocal premature (ectopic) ventricular contractions, premature (ectopic) ventricular contractions of multifocal origin, paired premature ventricular contractions (couplets), and episodes of ventricular tachycardia. Persistent ventricular tachycardia is usually treated with DC conversion.

Side Effects

The major toxic reactions to disopyramide administration include hypotension, congestive heart failure, and conduction disturbances. These effects are the result of disopyramide’s ability to depress myocardial contractility and myocardial conduction. Although disopyramide initially may produce ventricular tachyarrhythmias or ventricular fibrillation in some patients, the incidence of disopyramide-induced syncope in long-term therapy is not known. Most other toxic reactions (e.g., dry mouth, blurred vision, constipation) can be attributed to the anticholinergic properties of the drug.
CNS stimulation and hallucinations are rare.The incidence of severe adverse effects in long-term therapy may be lower than those observed with quinidine or procainamide.

Synthesis

Disopyramide, |á-(2-diisopropylaminoethyl)-|á-phenyl-2-pyridineacetamide (18.1.6), is synthesized by arylating benzylcyanide with 2-chloropiridine in the presence of sodium amide and subsequent alkylation of the resulting |á-phenyl-|á-(2-pyridyl) acetonitrile (18.1.4) with 2-diisopropylaminoethylchloride using sodium amide. Sulfuric acid hydrolysis of the resulting nitrile (18.1.5) leads to the formation of |á-(2-diisopropylaminoethyl)- |á-phenyl-2-pyridineacetamide, disopyramide.

Synthesis_3737-09-5

Drug interactions

In the presence of phenytoin, the metabolism of disopyramide is increased (reducing its effective concentration) and the accumulation of its metabolites is also increased, thereby increasing the probability of anticholinergic adverse effects. Rifampin also stimulates the hepatic metabolism of disopyramide, reducing its plasma concentration.
Unlike quinidine, disopyramide does not increase the plasma concentration of digoxin in patients receiving a maintenance dose of the cardiac glycoside. Hypoglycemia has been reported with the use of disopyramide, particularly in conjunction with moderate or excessive alcohol intake.

Metabolism

Hepatic

Precautions

Disopyramide should not be administered in cardiogenic shock, preexisting second- or third-degree A-V block, or known hypersensitivity to the drug. Neither should it be given to patients who are poorly compensated or those with uncompensated heart failure or severe hypotension. Because of its ability to slow cardiac conduction, disopyramide is not indicated for the treatment of digitalis-induced ventricular arrhythmias.
Patients with congenital prolongation of the QT interval should not receive quinidine, procainamide, or disopyramide because further prolongation of the QT interval may increase the incidence of ventricular fibrillation. Because of its anticholinergic properties, disopyramide should not be used in patients with glaucoma. Urinary retention and benign prostatic hypertrophy are also relative contraindications to disopyramide therapy. Patients with myasthenia gravis may have a myasthenic crisis after disopyramide administration as a result of the drug’s local anesthetic action at the neuromuscular junction.The elderly patient may exhibit increased sensitivity to the anticholinergic actions of disopyramide. Caution is advised when disopyramide is used in conjunction with other cardiac depressant drugs, such as verapamil, which may adversely affect atrioventricular conduction.

References

1) Hell?et al.?(1978),?Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias; Drugs?115?331 2) Verlinden?et al.?(2015),?Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug; Pharmacotherapy,?35?1164 3) Nakajima?et al.?(1989),?Anti-Cholinergic Effects of Quinidine, Disopyramide, and Procainamide in Isolated Atrial Myocytes: Mediation by Different Molecular Mechanisms; Circ. Res.,?64?297

Properties of DISOPYRAMIDE

Melting point: 94.5-950C
Boiling point: 475.43°C (rough estimate)
Density  1.0779 (rough estimate)
refractive index  1.6300 (estimate)
storage temp.  Inert atmosphere,Room Temperature
solubility  Soluble in DMSO (25 mg/ml) and Ethanol (>35 mg/mL)
form  solid
pka 10.2; also reported as 10.45(at 25℃)
color  White
Water Solubility  6.17mg/L(22.5 ºC)
Merck  14,3360
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
CAS DataBase Reference 3737-09-5(CAS DataBase Reference)

Safety information for DISOPYRAMIDE

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
ghs
Health Hazard
GHS08
GHS Hazard Statements H302:Acute toxicity,oral
H361:Reproductive toxicity
Precautionary Statement Codes P201:Obtain special instructions before use.
P308+P313:IF exposed or concerned: Get medical advice/attention.

Computed Descriptors for DISOPYRAMIDE

Related products of tetrahydrofuran

You may like

  • 0/5/37 DISOPYRAMIDE 99%
    0/5/37 DISOPYRAMIDE 99%
    0/5/37
    View Details
  • Disopyramide 95% CAS 3737-09-5
    Disopyramide 95% CAS 3737-09-5
    3737-09-5
    View Details
  • Disopyramide CAS 3737-09-5
    Disopyramide CAS 3737-09-5
    3737-09-5
    View Details
  • 4-(DIISOPROPYLAMINO)-2-PHENYL-2-(2-PYRIDINYL)BUTANAMIDE CAS 3737-09-5
    4-(DIISOPROPYLAMINO)-2-PHENYL-2-(2-PYRIDINYL)BUTANAMIDE CAS 3737-09-5
    3737-09-5
    View Details
  • Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    54094-19-8
    View Details
  • 85-81-4 99%
    85-81-4 99%
    85-81-4
    View Details
  • 208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2
    View Details
  • Meldrums acid 2033-24-1 99%
    Meldrums acid 2033-24-1 99%
    2033-24-1
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.